-
New data show durable response following treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
in PRESS RELEASE 2023 on…
-
-
Royalty Pharma and Ferring Pharmaceuticals enter into US $500 million royalty agreement for new intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)
in PRESS RELEASE 2023 on -
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
in PRESS RELEASE 2023 onAd hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals appoints new…
-
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
in PRESS RELEASE 2023 onFour Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the…
-
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
in PRESS RELEASE 2023 onFerring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in…
-
Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle® (follitropin delta) at the congress of the Pacific Society for Reproductive Medicine
in PRESS RELEASE 2023 onFerring announces abstract of the first prospective, multi-national, real-world study of Rekovelle®…
-
Approval of new medicines in 2022 sets Ferring on course for future growth and diversification
in PRESS RELEASE 2023 onApproval of new medicines in 2022 sets Ferring on course for future…
-
Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer
in PRESS RELEASE 2023 onFerring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer…
PRESS RELEASE 2023
PRESS RELEASE 2023
